But Remestemcel failed to show any improvement in cardiac performance. In what way do you think it would have a role in this indication?
And... No successful RCT, no approval. A trend worthy of further investigation. Do a proper trial to show efficacy exists or not. Previously it was claimed that it helped improve CHF. Then the next trial couldn't replicate the result...
But Remestemcel failed to show any improvement in cardiac...
-
- There are more pages in this discussion • 5,421 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |